Which of the following are current prognostic indicators for canine cutaneous and subcutaneous mast cell tumors?

• A. KIT, Ki67, and BAX
• B. Ki67, BAX, and Histologic grading scheme
• C. KIT, BAX, and Histologic grading scheme
• D. KIT, Ki67, BAX, and Histologic grading scheme

Answer: (D)

Prognosis in canine cutaneous and subcutaneous mast cell tumors is guided by tumor biology markers that reflect how aggressive the tumor is, not just its size or appearance. KIT status captures the activity of the c-KIT receptor; activating mutations and abnormal KIT localization patterns are linked to more malignant behavior and a higher risk of spread, so evaluating KIT provides important prognostic information. Ki-67 shows how many tumor cells are actively proliferating; a higher Ki-67 index means the tumor is growing more quickly and tends to have a worse outcome. BAX relates to the cell’s propensity to undergo apoptosis; its level and balance with anti-apoptotic factors help gauge the tumor’s ability to resist cell death, which can influence prognosis though findings can be variable across studies. Histologic grading schemes, such as the Patnaik or the Kiupel system, summarize cellular morphology and invasion patterns into categories that consistently correlate with outcome, with higher grades indicating poorer prognosis. Taken together, KIT status, Ki-67 proliferation index, BAX-related apoptotic potential, and histologic grade provide a comprehensive, modern framework for prognostication.